



# AI Clinical Research

# NEWSLETTER



Welcome to the **May** edition of AICR's Newsletter, where we bring you the latest updates and advancements from our company.

As we strive to push the boundaries of medical innovation, we are excited to share with you some of the research initiatives achieved by our dedicated team.

## News

- Ongoing studies
- Future studies
- New partners
- EMA updates



01/02



## Ongoing studies

In different therapeutic areas:  
Covid-19, Schizophrenia and RIE-  
Ther (medical device).

We continued our site  
management and monitoring  
activities, effectively assisting both  
our investigators and patients.

## Future studies

- Studies in the initial stages of start-up and preparation, in two different therapeutic areas: Active Rheumatoid Arthritis & Benign Prostatic Hyperplasia

## New partners

We are proud to announce that AICR is now part of **ACE-REACT**

-Alliance for Clinical Excellence in Research and Clinical Trials

- <https://www.linkedin.com/company/67748894/admin/feed/posts/>

## EMA updates

- EMA's human medicines committee (CHMP) recommends to suspend or not grant the marketing authorizations for a number of generic medicines tested by Synapse Labs Pvt. Ltd. The CHMP's recommendation is sent to the European Commission which will issue a legally binding decision in due course.
- <https://www.ema.europa.eu/en/medicines/human/referrals/synapse>

Thank you for your continued support and  
collaboration.  
We look forward to sharing more exciting  
updates and insights with you in the  
months ahead.

02/02



AI Clinical Research

Iulia Tăbăcaru  
MD, CEO



0040 723 168 676



info@aiclinicalresearch.ro  
iulia.tabacaru@aiclinicalresearch.ro



www.aiclinicalresearch.ro



20 Calea Martirilor 1989 Street, room 3,  
floor 2, 300 719 Timisoara, Romania